May 31, 2024 08:00 AM EDTUpdated 11:23 AM

#ASCO24: Gilead presents more data on failed Trodelvy lung cancer study

Kyle LaHucik

Senior Reporter

CHICAGO — Researchers on Friday afternoon pulled back the curtain on Gilead’s previously announced Phase 3 failure in certain forms of non-small cell lung cancer. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO24: Gilead presents more data on failed Trodelvy lung cancer study

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Secretive Treeline Biosciences discloses $421M financing in filing

House’s prominent China critic Jim McGovern leads opposition to Biosecure Act: ‘I would prefer to go back to the ...

BenevolentAI CEO is out after less than a year on the job

FDA approves AbbVie's 24-hour Parkinson's infusion therapy after two CRLs

Sage shakes up senior management, slashes pipeline, sheds 33% of staff

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

#AS­CO24: Gilead presents more da­ta on failed Trodelvy lung can­cer study

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

#ASCO24: Gilead presents more data on failed Trodelvy lung cancer study